Trial Profile
A Randomized Clinical Trial to Study the Efficacy, Safety, and Tolerability of MK-8291 in Subjects With Post-Herpetic Neuralgia With Allodynia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs MK 8291 (Primary)
- Indications Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 11 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 22 Feb 2016 Planned End Date changed from 1 Mar 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
- 22 Feb 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.